News
MDBIF
--
NaN%
--
TrivarX Limited Advances Acquisition of Innovative Brain Imaging Technology
TipRanks · 3d ago
TrivarX Advances Mental Health Diagnostics and Expands into Neuro-Oncology
TipRanks · 10/30 23:40
TrivarX Limited Issues 5 Million Unlisted Options
TipRanks · 10/29 02:08
TrivarX Limited Announces Quotation of New Securities on ASX
TipRanks · 10/27 00:38
TrivarX Limited Announces New Securities Issuance
TipRanks · 10/27 00:28
TrivarX Limited Announces Proposed Securities Issue
TipRanks · 10/22 03:38
TrivarX Limited Announces 2025 Annual General Meeting Details
TipRanks · 10/22 03:09
TrivarX Completes Patient Recruitment in Veteran Mental Health Trial
TipRanks · 10/21 22:40
TrivarX Limited Announces Significant Securities Issue
TipRanks · 10/16 00:10
TrivarX Limited Announces Proposed Securities Issuance
TipRanks · 10/16 00:10
TrivarX Limited Acquires Stabl-Im Technology for Enhanced Brain Tumor Detection
TipRanks · 10/16 00:10
TrivarX Extends Trading Suspension Amid Acquisition Plans
Barchart · 10/13 18:10
TrivarX Reports Promising Interim Results in Veteran Mental Health Trial
Barchart · 10/08 19:12
TrivarX Limited Initiates Trading Halt Ahead of Major Announcement
Barchart · 10/07 18:08
TrivarX Limited Announces Cessation of 100,000 Securities
Barchart · 10/02 22:54
TrivarX Limited Announces Change in Director’s Securities Holdings
Barchart · 10/02 22:54
More
Webull provides a variety of real-time MDBIF stock news. You can receive the latest news about TrivarX through multiple platforms. This information may help you make smarter investment decisions.
About MDBIF
TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.